

ASCO20 Virtual Scientific Meeting



View from the **Willis Tower** (**Sears Tower**, its name for 36 years)

ASCO Press Release:

ALEXANDRIA, Va. – This year the American Society of Clinical Oncology (ASCO) will deliver the latest cancer science to the global oncology community in a new virtual format. Advances in immunotherapies and targeted therapies for lung, colorectal, ovarian, and bladder cancers; improvements in access to cancer care, as well as the impact of COVID-19 on people with cancer are among the topics that will be highlighted in the ASCO20 Virtual Scientific Program's official Press Program.

The ASCO20 Virtual Scientific Program, to be held May 29-31, will provide an engaging lineup of scheduled and on-demand scientific content across a variety of approaches, disciplines, and specialties. The theme of this year's meeting is Unite and Conquer: Accelerating Progress Together.

Approximately 2,215 abstracts were accepted for presentation during the ASCO20 Virtual Scientific Program, and more than 3,400 additional abstracts were accepted for online publication. The vast majority of these abstracts will be publicly posted on abstracts.asco.org on Wednesday, May 13, at 5:00 p.m. ET. Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released online on Thursday, May 28, at 5:00 p.m. ET.

Oncoletter provides you with links to some oral abstract sessions as well as links to interviews about papers presented at the ASCO20 Virtual Scientific Meeting.

[Navigation überspringen](#)

[Studies presented at press briefings](#) [Studies presented at press briefings](#)

[Pre-Meeting Presentation](#) [Olaparib maintenance Extends Survival in Relapsed BRCA-mutated Ovarian Cancer](#); [Quitting Smoking at Any Point Improves Chances of Lung Cancer Survival](#); [Videoconference Intervention Reduces Anxiety & Distress Among Remote Caregivers](#); [Geriatric Assessment](#)

[Press Briefing May 28](#) [COVID-19 & azithromycin/hydroxychloroquine](#); [COVID-19 in thoracic cancer](#); [pembrolizumab in ACC](#); [osimertinib in NSCLC & EGFR mutation](#); [avelumab in advanced bladder cancer](#); [avelumab in gestational trophoblastic tumor](#); [precision medicine for pediatric cancer](#)

[Plenary Session Abstracts](#) [JAVELIN Bladder 100: systemic therapy \(ST\) + early local therapy vs ST alone in de novo stage IV BC](#); [KRd vs VRd initial in NDMM \(ENDURANCE\)](#); [Pembro vs CT for MSI-High/MM Repair Deficient mCC](#); [KEYNOTE-177: Osimertinib adjuvant in stage IB–IIIA EGFRm NSCLC](#)

[Oral Sessions](#) [Abstracts available except late breaking abstracts](#)

[Breast Cancer I](#) [Local/Regional/Adjuvant](#)

[Breast Cancer II](#) [metastatic](#)

[Brustkrebs Interviews](#) [Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Nadia Harbeck \(HER2\), Christian Jackisch \(Hormon+\), Wolfgang Janni \(Olaparib\), Volkmar Müller \(Demenzrisiko, Palliativ\), Michael Untch \(triple negativ\)](#)

[Gynecologic Cancer](#) [Except Breast](#)

[Gynäkologische Karzinomata - Interviews](#) [Renate Haidinger, Brustkrebs Deutschland e.V. im Interview mit Sven Mahner, Hamburg \(Ovarialkarzinom: Operative Fortschritte & Olaparib; Zelltherapie\)](#)